Joseph DosSantos is the Chief Financial Officer at RFH. Joe, a growth-focused CFO with extensive experience in corporate finance, capital markets, and financial operations, joined RFH in December of 2025 to help lead RFH into the next chapter of expanded growth focused on partnership development and elevation of value based-care programming.
Joe is an accomplished finance executive with extensive experience leading financial strategy, capital markets activities, IPO-readiness initiatives, and operational finance across public and private life sciences organizations.
He most recently served two terms at Celularity, Inc. (Nasdaq: CELU), a regenerative and cellular medicines company. He rejoined the company in April 2024 as Senior Vice President, Finance, and was appointed Interim Chief Financial Officer in June 2025, serving through December 2025. He previously held the Senior Vice President, Finance role from August 2017 to August 2021.
From January 2023 to April 2024, Joe was Chief Financial Officer of Defender Pharmaceuticals, Inc., a privately held life sciences company focused on advancing medical countermeasures and health therapies for both civilian and military populations. Prior to that, he served as Chief Financial Officer of Luzsana Biotechnology, Inc. (2021–2022), a U.S.-based subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd., where he helped shape the U.S. financial and operational infrastructure for one of the world’s leading biopharmaceutical companies.
DosSantos is a licensed Certified Public Accountant (CPA). He holds a Bachelor of Science in Accountancy from Kean University and a Master of Business Administration in Finance from Seton Hall University.
